Company news

ARS Pharmaceuticals, Inc. news in 2023

ARS Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updates

November 8, 2023

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 8, 2023

ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)

October 5, 2023

Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology

October 2, 2023

FDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Study

September 18, 2023

ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 9, 2023

ARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

June 19, 2023

ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results

May 14, 2023

FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

May 10, 2023

ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis

May 8, 2023

ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis

March 27, 2023

ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

March 22, 2023

ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors

February 22, 2023

ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis

February 21, 2023

ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023

February 8, 2023

Decks in 2023